Cepheid Charge Into Clinical Diagnostics Led By Ex-Vysis Executives
This article was originally published in The Gray Sheet
Executive Summary
Cepheid expects its clinical test for group B strep to reach the U.S. market early in 2003, marking the life sciences firm's entry into clinical testing for infectious diseases
You may also be interested in...
DoD Needs NAT-Immunodiagnostics Pairing; Project BioShield Funds Emerge
The U.S. Army Medical Research Institute of Infectious Diseases hopes to cultivate the development of an integrated diagnostic platform for medical defense against biological warfare threats by 2008
DoD Needs NAT-Immunodiagnostics Pairing; Project BioShield Funds Emerge
The U.S. Army Medical Research Institute of Infectious Diseases hopes to cultivate the development of an integrated diagnostic platform for medical defense against biological warfare threats by 2008
Cepheid/Infectio Diagnostic Partnership Bears First Fruit: IDI-Strep B Test
Infectio Diagnostic's IDI-Strep B Group B streptococcus (GBS) laboratory test detects about 94% of strep in pregnant women and is more rapid than standard screening methods, FDA says